The Use of Complementary Medicines is Relatively High Among Patients in Phase III Cancer Trials
Complementary medicines are mostly used by younger patients with better performance status and fewer sites of metastasis
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1551 results
ctDNA From Patients with Colon Cancer Is Indicative of Outcome Following 3 Versus 6 Months of Oxaliplatin-Based Adjuvant Treatment
Circulating tumour DNA prior to adjuvant chemotherapy is a marker for disease-free survival in patients with stage III colon cancer
The EPIPHANY Index Assesses Risk of Short-Term Serious Complications in Patients with Cancer and Pulmonary Embolism
The EPIPHANY index was validated in a prospective PERSEO study
Adjuvant Nivolumab Continues to Provide Superior Recurrence-Free Survival Benefit Over Ipilimumab at 3 Years in Patients with Resected Stage III or IV Melanoma
Long-term recurrence-free and distant metastasis-free survival favours adjuvant nivolumab over ipilimumab
Nivolumab Combined with Ipilimumab or Alone Outperforms Ipilimumab at 5 Years in Advanced Melanoma
Long-term data from the CheckMate 067 study
Treatment Tailored by Molecular Gene Expression Analysis Fails to Improve Outcome in Patients with CUP
Systemic treatment based on molecular analysis did not improve survival over empiric chemotherapy in patients with carcinomas of unknown primary site
tTMB Is Not Established as a Marker for Pembrolizumab Efficacy in NSCLC
Two exploratory analysis of the relationship between tissue tumour mutational burden and pembrolizumab efficacy provided conflicting findings
ESMO Congress 2019 Spotlight on Leptomeningeal Metastases
Presentations cover a new classification strategy that may be prognostic of outcome and a new treatment option for leptomeningeal metastases in NSCLC patients
Ceritinib Targets Brain Metastases in Patients with ALK-positive NSCLC
Lung cancer and other thoracic tumours; Anticancer agents and biologic therapy; Personalised medicine
Secondary Resectability Improved with Induction Chemotherapy in Locally Advanced Pancreatic Cancer
More patients were able to undergo resection following induction chemotherapy
Nivolumab Challenges Sorafenib as First-line Treatment in Advanced HCC
Nivolumab improved response and showed trend towards improved survival compared to sorafenib in the first-line setting in patients with advanced hepatocellular carcinoma
EMA Recommends Granting the Marketing Authorisation for Generic Arsenic Trioxide
Arsenic trioxide Accord is intended for the treatment of acute promyelocytic leukaemia